Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-11-09 DOI:10.1016/j.vaccine.2024.126503

Eunseon Gwak , Seung-Ah Choe , Erdenetuya Bolormaa , Young June Choe , Chengbin Wang , Jonathan Fix , Muruga Vadivale , Matthew D. Rousculp

{"title":"Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea","authors":"Eunseon Gwak , Seung-Ah Choe , Erdenetuya Bolormaa , Young June Choe , Chengbin Wang , Jonathan Fix , Muruga Vadivale , Matthew D. Rousculp","doi":"10.1016/j.vaccine.2024.126503","DOIUrl":null,"url":null,"abstract":"<div><div>To estimate the relative effectiveness of NVX-CoV2373 versus BNT162b2 (Pfizer–BioNTech) in preventing SARS-CoV-2 infection and severe COVID-19 disease during the Omicron variant dominance in South Korea, we conducted a retrospective cohort-study among ≥12-year-olds using the K-COV-N database, which links COVID-19 vaccine registry data with health insurance claims data. The Cox proportional-hazards model and inverse probability of treatment weighting were employed to calculate adjusted hazard ratios (aHRs). Among homologous primary-series NVX-CoV2373 versus BNT162b2 recipients at Day 180 post-vaccination, the aHR was 0.90 (95% CI: 0.87–0.93) for all laboratory-confirmed and 0.65 (95% CI: 0.48–0.88) for severe infections. Among homologous 1st-booster recipients, it was 1.15 (95% CI: 1.01–1.30) for all laboratory-confirmed and 0.39 (95% CI: 0.20–0.75) for severe infections. At 180-days post-immunization, we observed homologous, NVX-CoV2373 primary-series added and 1st booster offered comparable protection against SARS-CoV-2 infection versus BNT162b2.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126503"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X2401185X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To estimate the relative effectiveness of NVX-CoV2373 versus BNT162b2 (Pfizer–BioNTech) in preventing SARS-CoV-2 infection and severe COVID-19 disease during the Omicron variant dominance in South Korea, we conducted a retrospective cohort-study among ≥12-year-olds using the K-COV-N database, which links COVID-19 vaccine registry data with health insurance claims data. The Cox proportional-hazards model and inverse probability of treatment weighting were employed to calculate adjusted hazard ratios (aHRs). Among homologous primary-series NVX-CoV2373 versus BNT162b2 recipients at Day 180 post-vaccination, the aHR was 0.90 (95% CI: 0.87–0.93) for all laboratory-confirmed and 0.65 (95% CI: 0.48–0.88) for severe infections. Among homologous 1st-booster recipients, it was 1.15 (95% CI: 1.01–1.30) for all laboratory-confirmed and 0.39 (95% CI: 0.20–0.75) for severe infections. At 180-days post-immunization, we observed homologous, NVX-CoV2373 primary-series added and 1st booster offered comparable protection against SARS-CoV-2 infection versus BNT162b2.

查看原文本刊更多论文

韩国同源 NVX-CoV2373 和 BNT162b2 COVID-19 疫苗接种的相对效果。

为了估算 NVX-CoV2373 与 BNT162b2（辉瑞生物技术公司）在韩国 Omicron 变异优势期预防 SARS-CoV-2 感染和严重 COVID-19 疾病的相对有效性，我们利用 K-COV-N 数据库对年龄≥12 岁的儿童进行了回顾性队列研究，该数据库将 COVID-19 疫苗登记数据与医疗保险索赔数据联系在一起。研究采用了 Cox 比例危险模型和逆概率治疗加权法来计算调整后的危险比（aHRs）。在接种后第 180 天，同源初免系列 NVX-CoV2373 与 BNT162b2 接种者中，所有实验室确诊感染的 aHR 为 0.90（95% CI：0.87-0.93），严重感染的 aHR 为 0.65（95% CI：0.48-0.88）。在同源第 1 次加强免疫者中，所有实验室确诊的感染率为 1.15（95% CI：1.01-1.30），严重感染率为 0.39（95% CI：0.20-0.75）。在免疫后 180 天，我们观察到同源、添加 NVX-CoV2373 主系列和第一加强剂与 BNT162b2 相比，对 SARS-CoV-2 感染的保护效果相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.